immatics biotechnologies GmbH (NASDAQ:IMTXW) Short Interest Update

immatics biotechnologies GmbH (NASDAQ:IMTXW) saw a significant increase in short interest in August. As of August 31st, there was short interest totalling 14,100 shares, an increase of 15.6% from the August 15th total of 12,200 shares. Based on an average daily volume of 16,100 shares, the days-to-cover ratio is currently 0.9 days.

Institutional Investors Weigh In On immatics biotechnologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMTXW. Virtu Financial LLC bought a new position in immatics biotechnologies in the 4th quarter valued at $28,000. Jefferies Financial Group Inc. acquired a new position in shares of immatics biotechnologies during the fourth quarter valued at $80,000. Alyeska Investment Group L.P. bought a new position in immatics biotechnologies in the fourth quarter valued at about $529,000. Walleye Capital LLC increased its position in immatics biotechnologies by 25.7% in the second quarter. Walleye Capital LLC now owns 260,079 shares of the company’s stock worth $889,000 after purchasing an additional 53,153 shares during the period. Finally, JPMorgan Chase & Co. increased its position in immatics biotechnologies by 11.9% in the second quarter. JPMorgan Chase & Co. now owns 378,197 shares of the company’s stock worth $1,293,000 after purchasing an additional 40,168 shares during the period.

immatics biotechnologies Stock Performance

Shares of NASDAQ:IMTXW opened at $3.57 on Tuesday. The business has a fifty day moving average of $3.61 and a 200-day moving average of $2.80. immatics biotechnologies has a twelve month low of $1.20 and a twelve month high of $4.14.

immatics biotechnologies Company Profile

immatics is a clinical-stage biopharmaceutical company active in the discovery and development of t-cell redirecting immunotherapies for the treatment of cancer. our transformative product candidates are – best in class – adoptive cell therapies and bispecific tcr molecules. these products are directed against tumor targets that have been identified and validated by immatics’? proprietary and world-leading xpresident® technology.